132 related articles for article (PubMed ID: 12877791)
1. A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
Zhu J; Ye P
Chin Med J (Engl); 2003 Jun; 116(6):840-3. PubMed ID: 12877791
[TBL] [Abstract][Full Text] [Related]
2. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
3. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
4. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients.
Koanantakul B; Jeamanukulkit N; Piamsomboon C; Chawantanpipat C; Khanacharoen I
J Med Assoc Thai; 2004 Nov; 87(11):1281-5. PubMed ID: 15825700
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
[TBL] [Abstract][Full Text] [Related]
7. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate.
Levin A; Duncan L; Djurdjev O; Shapiro RJ; Frohlich J; Belanger A; Dumas R; Ross S
Clin Nephrol; 2000 Feb; 53(2):140-6. PubMed ID: 10711416
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
Maciejewski S; Hilleman D
Pharmacotherapy; 2008 May; 28(5):570-5. PubMed ID: 18447655
[TBL] [Abstract][Full Text] [Related]
9. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
Wu TJ; Ou HY; Chou CW; Hsiao SH; Lin CY; Kao PC
Ann Clin Lab Sci; 2007; 37(2):158-66. PubMed ID: 17522372
[TBL] [Abstract][Full Text] [Related]
10. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
Winkler K; Weltzien P; Friedrich I; Schmitz H; Nickell HH; Hauck P; Hoffmann MM; Baumstark MW; Wieland H; März W
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):241-7. PubMed ID: 15146369
[TBL] [Abstract][Full Text] [Related]
11. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
Ceska R; Sobra J; Kvasnicka J; Procházková R; Kvasilová M; Haas T
Cas Lek Cesk; 1996 Jul; 135(13):413-6. PubMed ID: 8925538
[TBL] [Abstract][Full Text] [Related]
12. [Pleiotropic effect of the micronized fenofibrate: the reduction of plasma chlamydia pneumoniae antibody levels in patients with coronary artery disease].
Márk L; Márki-Zay J; Orosz I; Kondacs A; Erdei F; Katona A
Orv Hetil; 2003 Apr; 144(16):765-8. PubMed ID: 12778627
[TBL] [Abstract][Full Text] [Related]
13. [Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia].
Okopień B; Cwalina Ł; Haberka M; Kowalski J; Zieliński M; Szwed Z; Kalina Z; Herman ZS
Pol Merkur Lekarski; 2002 Dec; 13(78):465-9. PubMed ID: 12666442
[TBL] [Abstract][Full Text] [Related]
14. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
Farnier M; Freeman MW; Macdonell G; Perevozskaya I; Davies MJ; Mitchel YB; Gumbiner B;
Eur Heart J; 2005 May; 26(9):897-905. PubMed ID: 15781429
[TBL] [Abstract][Full Text] [Related]
16. [Effect of micronized fenofibrate (lipantyl-200M) on synthesis of cholesterol in peripheral blood lymphocytes of patients with ischemic heart disease and hyperlipidemia].
Ivanova TN; Poliakova ED; Olfer'ev AM; Perova NV
Biull Eksp Biol Med; 1998 May; 125(5):569-73. PubMed ID: 9644562
[No Abstract] [Full Text] [Related]
17. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
[TBL] [Abstract][Full Text] [Related]
18. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
Arca M; Montali A; Pigna G; Antonini R; Antonini TM; Luigi P; Fraioli A; Mastrantoni M; Maddaloni M; Letizia C
Metabolism; 2007 Nov; 56(11):1534-41. PubMed ID: 17950105
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Bays H; Rhyne J; Stein E; Rotenberg K; Doyle R
Clin Ther; 2005 Jun; 27(6):715-27. PubMed ID: 16117978
[TBL] [Abstract][Full Text] [Related]
20. [level of 7alpha-hydroxycholesterol in blood plasma as an indicator of cholesterol catabolism in hyperlipidemia and with hypolipidemic therapy].
Poliakova ED; Ivanova TN; Voshchinnikov EI; Olfer'ev AM; Perova NV
Vopr Med Khim; 2000; 46(2):168-75. PubMed ID: 10885038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
